Mehlika Toy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mehlika Toy has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Samuel So
Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA
10 shared publicationsDavid W. Hutton
Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA
4 shared publications- Samuel So
Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA
4 shared publications - Mindie H. Nguyen
Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
3 shared publications Bin Wei
Asian Liver Center, Department of Surgery, Stanford University School of Medicine, 780 Welch Road, CJ130D, Palo Alto, CA, 94304, USA
2 shared publicationsDavid Hutton
Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA
2 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (9) , 103324
Chronic hepatitis B in a large private hospital network in Türkiye: Clinical characteristics and electronic health record-data gaps
- 25 July 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (9) , 103324
Open AccessChronic hepatitis B in a large private hospital network in Türkiye: Clinical characteristics and electronic health record-data gaps
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (4) , 361-373
Prevalence of metabolic dysfunction-associated steatotic liver disease among obese, overweight, and at-risk children and adolescents in Türkiye: A meta-analysis
Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide. Among children, the overall prevalence of MASLD is estimated at around 7%, and early manifestation is associated with a more severe prognosis. Despite this growing burden, no systematic analysis of pediatric MASLD prevalence in Türkiye has yet been conducted. Here, we aimed to estimate the pediatric MASLD prevalence among children with specific conditions in Türkiye. Materials and Methods: A comprehensive literature search was conducted for studies published in English and/or Turkish between 2005 and 2023 using the databases MED-LINE, PubMed, EMBASE, and ULAKBIM. The search strategy included the following terms: “Türkiye AND NAFLD AND Pediatric” and “Türkiye AND NAFLD AND Prevalence AND Chil-dren AND Adolescent.” The studies identified through this literature review were incor-porated into the meta-analysis, which included either obese/overweight or at-risk chil-dren or adolescents with specific conditions such as increased transaminases. Results: The pooled overall prevalence of MASLD was estimated as 44.6% (95% confi-dence interval [CI]: 39.5–49.7) among at-risk children and adolescents. Heterogeneity among studies was considerable, with an I2 value of 96%, indicating substantial variabil-ity. Subgroup analysis showed a pooled prevalence of 54.9% in boys (95% CI: 48.6–61.1) and 41.2% in girls (95% CI: 35.6–46.9). Regionally, the prevalence was 49.0% (95% CI: 41.2–57.1) in the Marmara and Aegean regions, and 42.2% (95% CI: 35.3–49.1) in the Black Sea, Mediterranean, and Central Anatolian regions. Conclusion: The results of this study indicate a markedly high prevalence of MASLD among at-risk children and adolescents. These findings should serve as an alert for policymakers to adapt healthcare strategies aimed at preventing childhood obesity and MASLD.Materials and Methods: A comprehensive literature search was conducted for studies published in English and/or Turkish between 2005 and 2023 using the databases MEDLINE, PubMed, EMBASE, and UlakBim. The search strategy included the following terms: “Türkiye AND NAFLD AND Pediatric” and “Türkiye AND NAFLD AND Prevalence AND Children AND Adolescent.” The studies identified through this literature review were incorporated into the meta-analysis, which included either obese/overweight or at-risk children or adolescents with specific conditions such as increased transaminases. Results: The pooled overall prevalence of MASLD was estimated as 44.6% (95% confidence intervals [CI]: 39.5–49.7) among at-risk children and adolescents. Heterogeneity among studies was considerable, with an I2 value of 96%, indicating substantial variability. Subgroup analysis showed a pooled prevalence of 54.9% in boys (95% CI: 48.6–61.1) and 41.2% in girls (95% CI: 35.6–46.9). Regionally, the prevalence was 49.0% (95% CI: 41.2–57.1) in the Marmara and Aegean regions, and 42.2% (95% CI: 35.3–49.1) in the Black Sea, Mediterranean, and Central Anatolian regions. Conclusion: The results of this study indicate a markedly high prevalence of MASLD among at-risk children and adolescents. These findings should serve as an alert for policymakers to adapt healthcare strategies aimed at preventing childhood obesity and MASLD.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (4) , 361-373
Prevalence of metabolic dysfunction-associated steatotic liver disease among obese, overweight, and at-risk children and adolescents in Türkiye: A meta-analysis
Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide. Among children, the overall prevalence of MASLD is estimated at around 7%, and early manifestation is associated with a more severe prognosis. Despite this growing burden, no systematic analysis of pediatric MASLD prevalence in Türkiye has yet been conducted. Here, we aimed to estimate the pediatric MASLD prevalence among children with specific conditions in Türkiye. Materials and Methods: A comprehensive literature search was conducted for studies published in English and/or Turkish between 2005 and 2023 using the databases MED-LINE, PubMed, EMBASE, and ULAKBIM. The search strategy included the following terms: “Türkiye AND NAFLD AND Pediatric” and “Türkiye AND NAFLD AND Prevalence AND Chil-dren AND Adolescent.” The studies identified through this literature review were incor-porated into the meta-analysis, which included either obese/overweight or at-risk chil-dren or adolescents with specific conditions such as increased transaminases. Results: The pooled overall prevalence of MASLD was estimated as 44.6% (95% confi-dence interval [CI]: 39.5–49.7) among at-risk children and adolescents. Heterogeneity among studies was considerable, with an I2 value of 96%, indicating substantial variabil-ity. Subgroup analysis showed a pooled prevalence of 54.9% in boys (95% CI: 48.6–61.1) and 41.2% in girls (95% CI: 35.6–46.9). Regionally, the prevalence was 49.0% (95% CI: 41.2–57.1) in the Marmara and Aegean regions, and 42.2% (95% CI: 35.3–49.1) in the Black Sea, Mediterranean, and Central Anatolian regions. Conclusion: The results of this study indicate a markedly high prevalence of MASLD among at-risk children and adolescents. These findings should serve as an alert for policymakers to adapt healthcare strategies aimed at preventing childhood obesity and MASLD.Materials and Methods: A comprehensive literature search was conducted for studies published in English and/or Turkish between 2005 and 2023 using the databases MEDLINE, PubMed, EMBASE, and UlakBim. The search strategy included the following terms: “Türkiye AND NAFLD AND Pediatric” and “Türkiye AND NAFLD AND Prevalence AND Children AND Adolescent.” The studies identified through this literature review were incorporated into the meta-analysis, which included either obese/overweight or at-risk children or adolescents with specific conditions such as increased transaminases. Results: The pooled overall prevalence of MASLD was estimated as 44.6% (95% confidence intervals [CI]: 39.5–49.7) among at-risk children and adolescents. Heterogeneity among studies was considerable, with an I2 value of 96%, indicating substantial variability. Subgroup analysis showed a pooled prevalence of 54.9% in boys (95% CI: 48.6–61.1) and 41.2% in girls (95% CI: 35.6–46.9). Regionally, the prevalence was 49.0% (95% CI: 41.2–57.1) in the Marmara and Aegean regions, and 42.2% (95% CI: 35.3–49.1) in the Black Sea, Mediterranean, and Central Anatolian regions. Conclusion: The results of this study indicate a markedly high prevalence of MASLD among at-risk children and adolescents. These findings should serve as an alert for policymakers to adapt healthcare strategies aimed at preventing childhood obesity and MASLD.
- Open Access
- 22 July 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (10) , 614-622
Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States
About 80% of persons with chronic hepatitis B virus (HBV) infection in the United States are non‐US‐born. Despite improvements in infant hepatitis B vaccination globally since 2000, work remains to attain the World Health Organization's (WHO) global 2030 goal of 90% vaccination. We explore the impacts on the United States of global progress in hepatitis B vaccination since 2000 and of achieving WHO hepatitis B vaccination goals. We simulated immigrants with HBV infection arriving to the United States from 2000 to 2070 using models of the 10 countries from which the largest numbers of individuals with HBV infection were born. We estimated costs in the United States among these cohorts using a disease simulation model. We simulated three scenarios: a scenario with no progress in infant vaccination for hepatitis B since 2000 (baseline), current (2020) progress and achieving WHO 2030 goals for hepatitis B vaccination. We estimate current hepatitis B vaccination progress since the 2000 baseline in these 10 countries will lead to 468,686 fewer HBV infections, avoid 35,582 hepatitis B‐related deaths and save $4.2 billion in the United States through 2070. Achieving the WHO 2030 90% hepatitis B infant vaccination targets could lead to an additional 16,762 fewer HBV infections, 989 fewer hepatitis B‐related deaths and save $143 million through 2070. Global hepatitis B vaccination since 2000 reduced prevalence of HBV infection in the United States. Achieving the WHO 2030 infant vaccination goals globally could lead to over one hundred million dollars in additional savings.
- 22 July 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (10) , 614-622
Open AccessModelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States
About 80% of persons with chronic hepatitis B virus (HBV) infection in the United States are non‐US‐born. Despite improvements in infant hepatitis B vaccination globally since 2000, work remains to attain the World Health Organization's (WHO) global 2030 goal of 90% vaccination. We explore the impacts on the United States of global progress in hepatitis B vaccination since 2000 and of achieving WHO hepatitis B vaccination goals. We simulated immigrants with HBV infection arriving to the United States from 2000 to 2070 using models of the 10 countries from which the largest numbers of individuals with HBV infection were born. We estimated costs in the United States among these cohorts using a disease simulation model. We simulated three scenarios: a scenario with no progress in infant vaccination for hepatitis B since 2000 (baseline), current (2020) progress and achieving WHO 2030 goals for hepatitis B vaccination. We estimate current hepatitis B vaccination progress since the 2000 baseline in these 10 countries will lead to 468,686 fewer HBV infections, avoid 35,582 hepatitis B‐related deaths and save $4.2 billion in the United States through 2070. Achieving the WHO 2030 90% hepatitis B infant vaccination targets could lead to an additional 16,762 fewer HBV infections, 989 fewer hepatitis B‐related deaths and save $143 million through 2070. Global hepatitis B vaccination since 2000 reduced prevalence of HBV infection in the United States. Achieving the WHO 2030 infant vaccination goals globally could lead to over one hundred million dollars in additional savings.
- Open Access
- 22 February 2024
- Published by Elsevier in IJID Regions
- Vol. 10, 228-234
Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence
- 22 February 2024
- Published by Elsevier in IJID Regions
- Vol. 10, 228-234
Open AccessHepatitis delta virus infection in Turkey: A meta-analysis of prevalence
- Open Access
- 28 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12298
Knowledge and Attitude Related to Hepatitis C among Medical Students in the Oral Direct Acting Antiviral Agents Era in Vietnam
Background: Medical students play important frontline roles in the prevention, early detection, and treatment of hepatitis C. This study investigated knowledge and attitudes toward hepatitis C among 5th- and 6th-year medical students and possible associated factors. Methods: A cross-sectional survey was conducted among 2000 students from eight medical universities using a self-administered structured questionnaire. Results: The mean knowledge and attitude scores for hepatitis C were 20.1 ± 4.0 (out of 26) and 10.6 ± 2.9 (out of 20), respectively. Approximately, three-quarters (74.4%) of the participants had a good knowledge score, but only a small proportion (3.1%) obtained a good attitude score. Although the participants had fairly high knowledge about the causes, consequences, and transmission routes of hepatitis C, there were important gaps in their knowledge about hepatitis C screening and treatment. In multivariate analysis, female students, 5th-year students, and students from the central provinces had significantly higher knowledge and attitude scores. There was a low positive correlation between knowledge and attitude scores. Conclusion: This study points out the need to update the medical training curriculum to improve the knowledge and attitude of students about hepatitis C infection.
- 28 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12298
Open AccessKnowledge and Attitude Related to Hepatitis C among Medical Students in the Oral Direct Acting Antiviral Agents Era in Vietnam
Background: Medical students play important frontline roles in the prevention, early detection, and treatment of hepatitis C. This study investigated knowledge and attitudes toward hepatitis C among 5th- and 6th-year medical students and possible associated factors. Methods: A cross-sectional survey was conducted among 2000 students from eight medical universities using a self-administered structured questionnaire. Results: The mean knowledge and attitude scores for hepatitis C were 20.1 ± 4.0 (out of 26) and 10.6 ± 2.9 (out of 20), respectively. Approximately, three-quarters (74.4%) of the participants had a good knowledge score, but only a small proportion (3.1%) obtained a good attitude score. Although the participants had fairly high knowledge about the causes, consequences, and transmission routes of hepatitis C, there were important gaps in their knowledge about hepatitis C screening and treatment. In multivariate analysis, female students, 5th-year students, and students from the central provinces had significantly higher knowledge and attitude scores. There was a low positive correlation between knowledge and attitude scores. Conclusion: This study points out the need to update the medical training curriculum to improve the knowledge and attitude of students about hepatitis C infection.
- Open Access
- 8 July 2022
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 04043
Costs and health impact of delayed implementation of a national hepatitis B treatment program in China
In response to the United Nations’ 2030 Sustainable Development Goal to combat viral hepatitis, in 2016 the WHO issued the first global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health problem by 2030 [1]. Endorsed by all WHO member states, including China, the strategy set important prevention and vaccination […]
- 8 July 2022
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 04043
Open AccessCosts and health impact of delayed implementation of a national hepatitis B treatment program in China
In response to the United Nations’ 2030 Sustainable Development Goal to combat viral hepatitis, in 2016 the WHO issued the first global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health problem by 2030 [1]. Endorsed by all WHO member states, including China, the strategy set important prevention and vaccination […]
- Open Access
- 19 March 2022
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 49 (7) , 517-525
Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections
Background: The estimated number of people living with hepatitis B virus (HBV) infection acquired through sexual transmission was 103,000 in 2018, with an estimated incidence of 8300 new cases per year. Although hepatitis B (HepB) vaccination is recommended by the Advisory Committee for Immunization Practices for persons seeking evaluation and treatment for sexually transmitted infections (STIs), prevaccination testing is not yet recommended. Screening may link persons with chronic hepatitis B to care and reduce unnecessary vaccination. Methods: We used a Markov model to calculate the health impact and cost-effectiveness of 1-time HBV testing combined with the first dose of the HepB vaccine for adults seeking care for STI. We ran a lifetime, societal perspective analysis for a hypothetical population of 100,000 aged 18 to 69 years. The disease progression estimates were taken from recent cohort studies and meta-analyses. In the United States, an intervention that costs less than $100,000 per quality-adjusted life-year (QALY) is generally considered cost-effective. The strategies that were compared were as follows: (1) vaccination without HBV screening, (2) vaccination and hepatitis B surface antigen (HBsAg) screening, (3) vaccination and screening with HBsAg and anti-HBs, and (4) vaccination and screening with HBsAg, anti-HBs, and anti-HBc. Data were obtained from Centers for Medicare & Medicaid services reimbursement, the Centers for Disease Control and Prevention vaccine price list, and additional cost-effectiveness literature. Results: Compared with current recommendations, the addition of 1-time HBV testing is cost-saving and would prevent an additional 138 cases of cirrhosis, 47 cases of decompensated cirrhosis, 90 cases of hepatocellular carcinoma, 33 liver transplants, and 163 HBV-related deaths, and gain 2185 QALYs, per 100,000 adults screened. Screening with the 3-test panel would save $41.6 to $42.7 million per 100,000 adults tested compared with $41.5 to $42.5 million for the 2-test panel and $40.2 to $40.3 million for HBsAg alone. Conclusions: One-time HBV prevaccination testing in addition to HepB vaccination for unvaccinated adults seeking care for STI would save lives and prevent new infections and unnecessary vaccination, and is cost-saving.
- 19 March 2022
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 49 (7) , 517-525
Open AccessCost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections
Background: The estimated number of people living with hepatitis B virus (HBV) infection acquired through sexual transmission was 103,000 in 2018, with an estimated incidence of 8300 new cases per year. Although hepatitis B (HepB) vaccination is recommended by the Advisory Committee for Immunization Practices for persons seeking evaluation and treatment for sexually transmitted infections (STIs), prevaccination testing is not yet recommended. Screening may link persons with chronic hepatitis B to care and reduce unnecessary vaccination. Methods: We used a Markov model to calculate the health impact and cost-effectiveness of 1-time HBV testing combined with the first dose of the HepB vaccine for adults seeking care for STI. We ran a lifetime, societal perspective analysis for a hypothetical population of 100,000 aged 18 to 69 years. The disease progression estimates were taken from recent cohort studies and meta-analyses. In the United States, an intervention that costs less than $100,000 per quality-adjusted life-year (QALY) is generally considered cost-effective. The strategies that were compared were as follows: (1) vaccination without HBV screening, (2) vaccination and hepatitis B surface antigen (HBsAg) screening, (3) vaccination and screening with HBsAg and anti-HBs, and (4) vaccination and screening with HBsAg, anti-HBs, and anti-HBc. Data were obtained from Centers for Medicare & Medicaid services reimbursement, the Centers for Disease Control and Prevention vaccine price list, and additional cost-effectiveness literature. Results: Compared with current recommendations, the addition of 1-time HBV testing is cost-saving and would prevent an additional 138 cases of cirrhosis, 47 cases of decompensated cirrhosis, 90 cases of hepatocellular carcinoma, 33 liver transplants, and 163 HBV-related deaths, and gain 2185 QALYs, per 100,000 adults screened. Screening with the 3-test panel would save $41.6 to $42.7 million per 100,000 adults tested compared with $41.5 to $42.5 million for the 2-test panel and $40.2 to $40.3 million for HBsAg alone. Conclusions: One-time HBV prevaccination testing in addition to HepB vaccination for unvaccinated adults seeking care for STI would save lives and prevent new infections and unnecessary vaccination, and is cost-saving.
- 8 August 2021
- Published by Wiley in Liver International
- Vol. 42 (1) , 16-25
The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia
Background & Aims: We aim to capture the economic impact of a potential cure for chronic hepatitis B infection (CHB) in three countries (USA, China and Australia) with different health systems and epidemics to estimate the threshold drug prices below which a CHB cure would be cost‐saving and/or highly cost‐effective.Methods: We simulated patients’ hepatitis B progression, under three scenarios: current long‐term suppressive antiviral therapy, functional cure defined as sustained undetectable HBsAg and HBV DNA, and partial cure defined as sustained undetectable HBV DNA only after a finite, 48‐week treatment.Results: Compared with current long‐term antiviral therapy, a 30% effective functional cure among patients with and without cirrhosis in the USA, China and Australia would yield 17.50, 17.32 and 20.42 QALYs per patient, and 20.61, 20.42 and 20.62 QALYs per patient respectively. In financial terms, for CHB patients with and without cirrhosis, this would be cost‐saving at a one‐time treatment cost under US$11 944 and US$6694, respectively, in the USA, US$1744 and US$1001 in China, and US$12 063 and US$10 983 in Australia.Conclusion: We show that in purely economic terms, a CHB cure will be highly cost‐effective even if effective in only 30% of treated patients. The threshold price for cure is largely determined by the current antiviral drug costs, since it will replace a daily antiviral pill that is inexpensive and effective, although not curative. The likely need for combination therapies to achieve cure will also present cost challenges. While cost‐effectiveness is important, it cannot be the only consideration, as cure will provide many benefits in addition to reduced liver disease and HCC, including eliminating the need for a long‐term daily pill and reducing stigma often associated with chronic viral infection.
- 8 August 2021
- Published by Wiley in Liver International
- Vol. 42 (1) , 16-25
The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia
Background & Aims: We aim to capture the economic impact of a potential cure for chronic hepatitis B infection (CHB) in three countries (USA, China and Australia) with different health systems and epidemics to estimate the threshold drug prices below which a CHB cure would be cost‐saving and/or highly cost‐effective.Methods: We simulated patients’ hepatitis B progression, under three scenarios: current long‐term suppressive antiviral therapy, functional cure defined as sustained undetectable HBsAg and HBV DNA, and partial cure defined as sustained undetectable HBV DNA only after a finite, 48‐week treatment.Results: Compared with current long‐term antiviral therapy, a 30% effective functional cure among patients with and without cirrhosis in the USA, China and Australia would yield 17.50, 17.32 and 20.42 QALYs per patient, and 20.61, 20.42 and 20.62 QALYs per patient respectively. In financial terms, for CHB patients with and without cirrhosis, this would be cost‐saving at a one‐time treatment cost under US$11 944 and US$6694, respectively, in the USA, US$1744 and US$1001 in China, and US$12 063 and US$10 983 in Australia.Conclusion: We show that in purely economic terms, a CHB cure will be highly cost‐effective even if effective in only 30% of treated patients. The threshold price for cure is largely determined by the current antiviral drug costs, since it will replace a daily antiviral pill that is inexpensive and effective, although not curative. The likely need for combination therapies to achieve cure will also present cost challenges. While cost‐effectiveness is important, it cannot be the only consideration, as cure will provide many benefits in addition to reduced liver disease and HCC, including eliminating the need for a long‐term daily pill and reducing stigma often associated with chronic viral infection.
- 1 May 2020
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 15 (3) , 208-212
Hepatitis B cure: modeling the economics of a potential cost of a cure
Purpose of review The cure for hepatitis C virus infection has raised hope for a potential hepatitis B virus (HBV) cure, but the high price tag has led to serious questions about the affordability, and thus to access for all. This review discusses cost-effectiveness models, affordability, and access to a potential new cure for chronic HBV infection. Recent findings A cure does not yet exist for HBV, but the antiviral treatments that are currently available help slow down the progression of disease. There is limited research in the area of cost-effectiveness and economic analysis comparing a potential cure. Our preliminary findings from modeling and economic threshold analysis show that cure could be potentially cost-effective or cost-saving. Governments can possibly use the results of economic models for price negotiations. The highest burden of the HBV infection is in low and middle-income countries. Given that the cost of current treatment has dropped dramatically in recent years as the first line treatments have come off patent, the price for a HBV cure needs to be reasonable and affordable to all people.
- 1 May 2020
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 15 (3) , 208-212
Hepatitis B cure: modeling the economics of a potential cost of a cure
Purpose of review The cure for hepatitis C virus infection has raised hope for a potential hepatitis B virus (HBV) cure, but the high price tag has led to serious questions about the affordability, and thus to access for all. This review discusses cost-effectiveness models, affordability, and access to a potential new cure for chronic HBV infection. Recent findings A cure does not yet exist for HBV, but the antiviral treatments that are currently available help slow down the progression of disease. There is limited research in the area of cost-effectiveness and economic analysis comparing a potential cure. Our preliminary findings from modeling and economic threshold analysis show that cure could be potentially cost-effective or cost-saving. Governments can possibly use the results of economic models for price negotiations. The highest burden of the HBV infection is in low and middle-income countries. Given that the cost of current treatment has dropped dramatically in recent years as the first line treatments have come off patent, the price for a HBV cure needs to be reasonable and affordable to all people.
- 1 September 2019
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 4 (9) , 668
The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment
- 1 September 2019
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 4 (9) , 668
The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment